Belgian biopharmaceutical company Celyad has selected Dr David Gilham to be its new vice president of research and development.
Currently a member of Celyad’s immuno-oncology scientific advisory board, Dr Gilham will resign from his post in August to fulfill his new role from 1 September.
Dr Gilham brings extensive experience in the field of CAR-T cells, with his research activity focused on engineering T-cells for cancer therapies and pre-clinical study development.
Before joining Celyad Dr Gilham was a Reader in the Institute of Cancer Sciences at the University of Manchester, and led the Manchester Cancer Research Centre’s clinical and experimental immunotherapy group.
Dr Gilham said: “I am truly excited to be joining Celyad at such an important time in its history.
“Engineering immune system T-cells to attack and eradicate cancer is at the leading edge of cancer research and I look forward to advancing Celyad’s unique portfolio of cell therapy candidates in the clinic.”